Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
Stopped early · Phase 2
Conditions studied: Chronic Myelogenous Leukemia - Chronic Phase
In brief
This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib
Key facts
- Study ID
- NCT00644878
- Run by
- Novartis Pharmaceuticals
- People needed
- 18
- Starts
- 2008-10-01
- Expected to finish
- 2012-03-01
- Last updated by the study team
- 2021-08-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC Norris Cancer Center Jane Anne Nohl — Los Angeles, California, United States
- Georgia Health Sciences University Dept. of MCG — Augusta, Georgia, United States
- Indiana Blood and Marrow Institute — Beech Grove, Indiana, United States
- University of Iowa Hospitals & Clinics Univ of Iowa Hosp & Clinic — Iowa City, Iowa, United States
- LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center — New Orleans, Louisiana, United States
- St. Agnes Hospital — Baltimore, Maryland, United States
- Cancer Centers of the Carolinas — Greenville, South Carolina, United States
- South Texas Institute of Cancer — Corpus Christi, Texas, United States
- Baylor College of Medicine - Breast Care Dan L Duncan Cancer Ctr — Houston, Texas, United States
- Central Utah Clinic Central Utah Clinic (7) — Provo, Utah, United States
- Froedert Memorial Lutheran Hospital Dept.ofFroedert Memorial — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.